Endocrine I Flashcards Preview

Board Review - B - Systems Pharmacology > Endocrine I > Flashcards

Flashcards in Endocrine I Deck (48)
1

tx strategy DM I

low carb diet
insulin replacement

2

tx strategy DM II

diet modify, exercise

3

tx gestational DM

dietary mod, exercise, insulin replacement of lifestyle mod fails

4

aspart

fast acting insulin

5

glulisine

fast acting insulin

6

lispro

fast acting insulin

7

regular insulin

short acting

8

postprandial glucose control

rapid acting

9

NPH

intermediate acting insulin

10

detemir

long acting insulin

11

glargine

long acting insulin

12

metformin

biguanide

13

biguanide MOA

decreased gluconeogenesis
increased glycolysis
increased peripheral glucose uptake (insulin sens)

14

first like therapy DM II

metformin

15

adverse metformin

GI upset
lactic acidosis - CI in renal insufficiency

16

insulin receptor

tyrosine kinase activity

liver - increase glucose stored as glycogen
muscle - increased glycogen and protein synthesis
fat - increased TG storage

17

chlorpropamide

first gen sulfonylurea

18

tolbutamide

first gen sulfonylurea

19

glumepriride

second gen sulfonylurea

20

glipizide

second gen sulfonylurea

21

glyburide

second gen sulfonylurea

22

sulfonylurea MOA

close K channel in beta cell membrane - cell depolarize
-result in insulin release - increased Ca influx

23

stimulate endogenous insulin in DM II

sulfonylurea

require islet function - useless DM I

24

adverse sulfonylurea

hypoglycemia

25

pioglitazone

glitazone/thiazolidinedione

26

glitazone/thiazolidinedione MOA

increased insulin sensitivity in peripheral tissue

binds PPAR-gamma nuclear transcription regulator

27

rosiglutazone

glitazone/thiazolidinedione

28

adverse glitazone/thiazolidinedione

weight gain
edema
hepatotoxic
increased risk of fracture

29

exenatide

GLP-1 analog

30

liraglutide

GLP-1 analog

31

GLP-1 analog MOA

insulin increase
decreased glucagon

32

adverse GLP-1 analog

N/V
pancreatitis

33

linagliptin

DPP-4 inhibitor

34

saxagliptin

DPP-4 inhibitor

35

sitagliptin

DPP-4 inhibitor

36

DPP-4 inhibitor MOA

increase insulin
decreased glucagon

37

adverse DPP-4 inhibitor

UTI
resp infection

38

pramlintide

amylin analog

39

MOA amylin analog

decreased gastricy emptying
decreased glucagon

40

adverse pramlintide

hypoglycemia, nausea, diarrhea

41

canagliflozin

SGLT-2 inhibitor

42

MOA canagliflozin

block reabsorption glucose in PCT

inhibitor of SGLT-2

43

adverse canagliflozin

glucosuria, UTI, vaginal yeast infection

44

acarbose

a-glucosidase inhibitor

45

miglitol

a-glucosiase inhibitor

46

a-glucosidase inhibitor MOA

inhibit intestinal brush border a-glucosidase
-delayed carb hydrolysis and glucose absorption

decreased postprandial hyperglycemia

47

adverse a-glucosidase inhibitor

GI disturbances

48

activation of PPAR-gamma

increase insulin sensitivity and levels of adiponectin